Lung cancer is the second most common cancer and the leading cause of cancer-related
death worldwide. Molecular imaging using [18 F] fluorodeoxyglucose Positron Emission …

Abstract The discovery of Epidermal Growth Factor Receptor (EGFR) mutations in Non Small
Cell Lung Cancer (NSCLC) launched the era of personalized medicine in advanced …

Previous studies have demonstrated a significant difference in clinical characteristics
between patients with non‑small cell lung cancer (NSCLC) harboring exon 19 deletion (19 …

Background: Accumulating data shows that exon 19 deletions and L858R, both activating
epidermal growth factor receptor mutations in non-small-cell lung cancers (NSCLCs), are …

Objectives In non-small cell lung cancer patients with acquired resistance to first-or second-
generation EGFR-TKIs, osimertinib is approved in the presence of the T790 M resistance …

Adenocarcinoma is the most common type of non-small cell lung cancer. Some causative
genomic alterations in epidermal growth factor receptor (EGFR), including deletions in exon …

The application of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs),
such as gefitinib, has shifted lung cancer treatment from empirical chemotherapy to targeted …

Clinical trials have shown that epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKIs) did not improve the survival of patients with EGFR-mutated non-small cell lung …

Three EGFR tyrosine kinase inhibitors have been compared to standard chemotherapy as
up-front treatment in patients with advanced EGFR-positive NSCLC. We performed a …

We make use of a very large dataset of non-small cell lung cancer specimens to examine
the molecular epidemiology of EGFR mutations, particularly with respect to rare and …